Bound Therapeutics LLC is structured around creating next generation healthcare solutions by developing RNA-based drugs for various diseases, immersive haptic surgical simulation, and artificial intelligence automated medical imaging analysis. The firm's business focus is anchored in commercialization of a proprietary miRNA therapeutics platform technology for the treatment of aggressive breast cancer held by Bound Therapeutics under a licensing agreements with Thomas Jefferson University. The firm's paradigm-disrupting microRNA therapeutics blocks cancer-promoting microRNAs with high efficacy and high specificity through a delivery system that targets cancer cells effectively.
